Want to see VSEE full AI Analyst Report?
VSee Health (VSEE) AI Stock Analysis
Top Page
VSee Health
(Other OTC:VSEE)
Low score primarily driven by weak financial performance with sustained losses and cash burn, compounded by unfavorable valuation from negative earnings. Mixed technical indicators offer only minor support.
VSee Health (VSEE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.55M
- Dividend Yield
- ―
- Average Volume (3M)
- 41.44K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 0.61
- Revenue Growth
- -9.31%
- EPS Growth
- 89.42%
- Country
- US
- Employees
- 209
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
VSee Health Business Overview & Revenue Model
Company Description
VSee Health, Inc. specializes in delivering virtual healthcare solutions. Their flagship offering, iDoc Telehealth, is specifically designed to manage and coordinate comprehensive care for severely ill individuals within various critical care environ...
VSee Health Financial Statement Overview
Summary
Persistent net losses, sharply lower gross margins, and consistent negative cash flows across all periods signal major operational challenges and fragile financial health.
Income Statement
22NegativeBalance Sheet
38NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.63M | 14.62M | 10.42M | 5.77M | 6.38M | 7.34M |
| Gross Profit | 4.76M | 7.36M | 7.18M | 3.83M | 4.84M | 5.92M |
| EBITDA | -9.03M | -9.18M | -3.30M | -1.79M | 0 | 386.34K |
| Net Income | -13.82M | -14.71M | -57.70M | -3.76M | -836.21K | 475.90K |
Balance Sheet | ||||||
| Total Assets | 16.73M | 22.41M | 19.99M | 805.79K | 2.61M | 117.94M |
| Cash, Cash Equivalents and Short-Term Investments | 454.15K | 5.27M | 326.12K | 118.73K | 230.66K | 760.01K |
| Total Debt | 1.88M | 2.44M | 9.55M | 543.00K | 517.13K | 0 |
| Total Liabilities | 9.14M | 16.96M | 20.01M | 5.11M | 2.61M | 4.55M |
| Stockholders Equity | 7.59M | 5.45M | -18.49K | -3.97M | 360.72K | 113.39M |
Cash Flow | ||||||
| Free Cash Flow | -6.32M | -3.48M | -5.84M | -636.93K | -1.45M | -600.11K |
| Operating Cash Flow | -6.31M | -3.45M | -5.79M | -632.60K | -1.45M | -600.11K |
| Investing Cash Flow | -143.21K | -29.93K | -26.14K | -4,335 | 110.12M | -116.73M |
| Financing Cash Flow | 6.83M | 8.42M | 6.02M | 525.00K | -109.32M | 118.09M |
VSee Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VSEE, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 1.91, above the 50-day MA of 1.68, and below the 200-day MA of 12.72, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.22 is Neutral, neither overbought nor oversold. The STOCH value of 90.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VSEE.
VSee Health Risk Analysis
VSee Health disclosed 62 risk factors in its most recent earnings report. VSee Health reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskVSee Health Peers Comparison
Overall Rating
AMWL53Neutral
TDOC52Neutral
ZCMD43Neutral- VSEE40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AMWL | 53Neutral | $216.52M | -2.67 | -33.27% | ― | -19.00% | 40.98% |
| TDOC | 52Neutral | $1.55B | -9.89 | -11.63% | ― | -2.38% | 32.73% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ZCMD | 43Neutral | $4.53M | -0.01 | -32.44% | ― | -49.58% | -31.56% |
| VSEE | 40Underperform | $1.43M | -0.05 | -400.87% | ― | -9.31% | 89.42% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VSEE | Vsee Health, Inc. | 1.78 | -77.42 | -97.75% | |
| TDOC | Teladoc Inc. | 8.51 | 0.37 | 4.55% | |
| ZCMD | Zhongchao Inc | 1.02 | -1070.34 | -99.90% | |
| AMWL | American Well Corporation | 12.73 | 7.64 | 150.10% | |
| ONMD | Onemednet Corp | 4.22 | -13.48 | -76.16% | |
| EUDA | Euda Health Holdings Limited | 17.70 | -29.70 | -62.66% |
VSee Health Corporate Events
VSee Health Announces 1-for-80 Reverse Stock Split
NeutralOn September 22, 2026, VSee Health, Inc. filed a Certificate of Amendment to implement a 1-for-80 reverse stock split of its common stock, effective at 5:00 p.m. Eastern on September 23, 2026, with split-adjusted trading to begin on September 24, 202...
VSee Health Pursues Private Equity Financing Strategy
NeutralVSee Health disclosed that it is issuing Commitment Fee Shares and additional common stock under a Strata Agreement through a private offering structure rather than a public securities issuance. The company is relying on exemptions under Section 4(a)...
VSee Health Shareholders Approve Reverse Split Flexibility
PositiveOn August 25, 2026, VSee Health, Inc. held its annual meeting of stockholders for the fiscal year ended December 31, 2026, with a quorum representing 50.65% of voting shares present in person or by proxy. Shareholders elected directors Kevin Lowdermi...
VSee Health Faces Nasdaq Trading Suspension and Delisting
NegativeOn September 24, 2025, VSee Health disclosed that it had fallen out of compliance with Nasdaq’s Bid Price Rule after its shares traded below $1.00 for 30 consecutive sessions, triggering an initial 180‑day cure period later extended to Se...
VSee Health Raises Capital Through Convertible Debt Financing
NeutralOn June 30, 2026, VSee Health, Inc. entered into a securities purchase agreement with institutional investor Labrys, issuing an unsecured convertible promissory note with a principal amount of $336,000, including a $36,000 original issue discount, an...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026